Published in Ann Oncol on September 15, 2016
The past and future of breast cancer treatment-from the papyrus to individualised treatment approaches. Ecancermedicalscience (2017) 0.75
Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet (2005) 17.75
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics (2000) 10.63
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst (2007) 7.44
Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet (2005) 5.94
Bring on the biomarkers. Nature (2011) 5.77
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med (2009) 5.69
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer. J Clin Oncol (2014) 3.40
TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer (2006) 3.25
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84
Testing for improvement in prediction model performance. Stat Med (2013) 2.62
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol (2015) 2.54
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol (2012) 2.50
Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol (2002) 2.39
Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. Arch Intern Med (2008) 2.35
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol (2013) 2.28
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst (2013) 2.28
One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol (2011) 2.24
The cross-validated adaptive signature design. Clin Cancer Res (2010) 2.12
Randomised comparisons of medical tests: sometimes invalid, not always efficient. Lancet (2000) 1.86
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med (2013) 1.84
Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer (2007) 1.70
Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med (2010) 1.55
Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest (2011) 1.46
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. JAMA Oncol (2016) 1.46
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol (2013) 1.41
Integrating biomarkers in clinical trials. Expert Rev Mol Diagn (2011) 1.24
Interpretation of microarray data in cancer. Br J Cancer (2007) 1.12
New challenges for 21st century clinical trials. Clin Trials (2007) 1.07
Quantifying discrimination of Framingham risk functions with different survival C statistics. Stat Med (2012) 1.06
Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol (2013) 1.04
Prognosis - what does the clinician associate with this notion? Stat Med (2000) 1.01
Clinical trials for predictive medicine. Stat Med (2012) 0.93
Omics-based clinical trial designs. Curr Opin Oncol (2013) 0.87
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. J Natl Cancer Inst (2016) 0.85
Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives. Biom J (2014) 0.84
Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine. Clin Cancer Res (2012) 0.82
Empirical extensions of the lasso penalty to reduce the false discovery rate in high-dimensional Cox regression models. Stat Med (2016) 0.81
Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer? Genet Med (2015) 0.81
Multidimensionality of microarrays: statistical challenges and (im)possible solutions. Mol Oncol (2011) 0.80
The diagnostic randomized clinical trial is the best solution for management issues in critical limb ischemia. J Clin Epidemiol (2004) 0.80
Diagnostic randomized controlled trials: the final frontier. Trials (2012) 0.79
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract (2016) 0.79
Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. Stat Med (2011) 0.77
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. Public Health Genomics (2015) 0.77
Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces. Biom J (2016) 0.76
Efficiency of study designs in diagnostic randomized clinical trials. Stat Med (2012) 0.76
Comparing diagnostic tests: trials in people with discordant test results. Stat Med (2012) 0.76
Statistical methods applied to omics data: predicting response to neoadjuvant therapy in breast cancer. Curr Opin Oncol (2014) 0.76
Two-stage adaptive cutoff design for building and validating a prognostic biomarker signature. Stat Med (2014) 0.76
The results of a quantitative overview of chemotherapy in advanced ovarian cancer: what can we learn? Bull Cancer (1993) 0.76